On February 11, the US Food and Drug Administration (FDA) approved mirdametinib for adults and children aged 2 years and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that cannot be completely resected.   

For more information, read the FDA announcement and the SpringWorks Therapeutics press release.

Posted on 2/12/2025